Studying fat and immune cells in melanoma tissue
Part of Cancer, Skin clinical trials.
This study looks at stored tissue samples from people treated for melanoma to understand how fat and inflammatory cells affect the tumor. By reviewing these samples, researchers hope to learn more about melanoma and maybe improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had melanoma treated between 2006 and 2015, or you were treated at The Christie hospital between 2014 and 2019.
- You have a biopsy sample (tissue sample) that can be reviewed.
- If your melanoma had special features (like spitzoid type), those are of interest.
- The entire cross-section of your skin with the tumor must be visible on the slide, so researchers can see the full area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This research study analyzes blood and tissue samples from melanoma patients to identify biological markers that could help doctors better understand and treat the disease. Researchers will examine archived tissue samples and blood work to develop improved diagnostic tools.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.